Biotech companies are going public at a clearly faster pace in 2026 than in 2025, while the broader U.S. IPO market has cooled since mid-year. The headline is directionally supported by the reporting, but “tech deals stall” overstates the evidence. Technology listings still happened in 2026, and the third-quarter slowdown was concentrated in a few large deals and affected the whole market rather than one sector.
The short answer
PwC reported 22 biotech IPOs raising $6.9 billion through September 30, 2026. For all of 2025, it counted seven biotech IPOs raising $1.4 billion. That is the cleanest year-over-year comparison available for biotech. Over the same period, the overall U.S. IPO market was uneven. Renaissance Capital’s October 1 review of the third quarter counted 30 U.S. IPO listings and $32.8 billion in proceeds, but $26.5 billion of that came from one offering, SK hynix’s U.S. listing. Excluding it, the quarter’s proceeds were $6.2 billion, as Renaissance reported.
Why the two headline numbers do not compare directly
Each figure comes from a different publisher, period, and definition. Keep them separate when you quote them.
| Source | Period | What is counted | Reported figure |
|---|---|---|---|
| PwC | Full-year 2025 and January 1 to September 30, 2026 | Biotech IPOs | 2025: 7 IPOs, $1.4 billion. 2026 to Sept. 30: 22 IPOs, $6.9 billion |
| Dealogic, as reported by ION Analytics | Year to date as of August 19, 2026 | U.S. biotech IPOs | 21 IPOs, $7.85 billion |
| Renaissance Capital | Q3 2026, reviewed October 1 | All U.S. IPO listings | 30 listings, $32.8 billion; $6.2 billion excluding SK hynix’s $26.5 billion offering |
| Wilson Sonsini | January 1 to June 30, 2026 (H1), with H1 2025 for comparison | Technology and life-sciences IPOs or direct listings above $75 million deal value | 37 in H1 2026 versus 18 in H1 2025; 15 technology IPOs and 16 life-sciences IPOs |
| ICR Capital | Q3 2026 | IPO issuance by count, by sector | Healthcare 45%; technology 15% |
The biotech totals from PwC and Dealogic are not a contradiction. The August figure covers a shorter window, and the later PwC total reflects a different cutoff and methodology. Proceeds should not be read as having fallen between the two reports unless the publishers’ definitions match, and the reporting does not establish that they do.
Recommended Free Tools
#1 Best Overall
What happened in technology
Technology did not stop. Wilson Sonsini counted 15 technology IPOs above its $75 million threshold in the first half of 2026. Its combined technology and life-sciences count rose from 18 in H1 2025 to 37 in H1 2026. The published sub-counts (15 technology and 16 life-sciences) add up to 31, so the remaining six in the combined figure fall into categories the summary does not break out. Read the 37 as the combined group, not as a sum of the two sectors.
The third quarter is where the picture weakened. Renaissance Capital described a slower-than-expected quarter and attributed the slowdown to AI spending concerns, a 19-year high in bond yields, resumed rate hikes, and late-quarter postponements. ICR Capital’s Q3 data put healthcare at 45% of IPO issuance by count and technology at 15%. Those numbers describe a quarter where healthcare led, not one where technology listings vanished. ICR and Renaissance do not use identical universes, so do not rank the two sectors head-to-head from them.
Why biotech could issue while other deals slowed
ION Analytics, drawing on Dealogic and adviser interviews, gives several reasons. Each is an adviser’s explanation rather than a tested cause.
- Scientific progress during the downturn. Companies kept generating clinical data while public markets were weak, and that data gave investors something concrete to evaluate.
- Specialist and generalist demand. Healthcare-focused funds returned, and some generalist investors joined them.
- Aftermarket performance. Recent biotech listings that traded well encouraged investors to take part in later follow-on offerings.
- M&A exits. Renewed acquisition activity gave earlier investors a way to exit and recycle capital into new deals.
- Pipeline replacement. One quoted adviser said large pharmaceutical companies need to refill pipelines ahead of patent expirations, which creates demand for new drug assets.
Charlie Kim, co-chair of Cooley’s global capital markets group, put the underlying logic in one line in his comments to ION Analytics: “Even when IPO markets slow down or close, science continues to go.”
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problemsThe reopening is selective
The biotech recovery is not a rising tide that lifts every company. ION Analytics reported that advisers pointed to clinical validation, experienced management, a clear regulatory path, and a large addressable market as the traits that helped issuers. Preclinical companies remained largely shut out. Phase 2, late Phase 2, and Phase 3 companies were better positioned.
Driehaus Capital Management’s snapshot points the same way, with a narrower scope. Among 11 biopharmaceutical IPOs through May 31, 2026, data from Jefferies Healthcare Equity Capital Markets showed 55% with a Phase 2 lead asset and 36% with a Phase 3 lead asset. The same cohort had a mean deal size of $345.2 million and a median of $345.0 million. Because it covers only 11 deals through an earlier cutoff, treat it as a description of that group, not as a full-year estimate.
Rank #4
How to read IPO numbers without being misled
- Check the period. A mid-year count, a year-to-date count, and a full-quarter count are not interchangeable.
- Check the threshold. A deal-value floor such as Wilson Sonsini’s $75 million excludes smaller listings that other sources may include.
- Check the sector. “Biotech,” “life sciences,” and “healthcare” are different groupings, and they change the totals.
- Separate counts from proceeds. A single large deal can dominate proceeds while the number of listings barely changes, as the third quarter showed.
- Check whether direct listings, cross-listings, or SPACs are included. Each source makes its own choice.
The reporting describes market conditions. It is not an investment recommendation, and a rise in IPO counts does not indicate how any single listed company will perform after its debut.
Quick Recap
“
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
